Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
The Commoditization Of GLP-1s: Why Viking's Maintenance Hedge Is Falling Short
06:03pm, Thursday, 05'th Feb 2026
Viking Therapeutics, Inc. faces significant challenges with VK2735, lacking differentiation from established obesity treatments like ZEPBOUND and WEGOVY. Phase 2 data highlight tolerability issues at
Why a $49 weight-loss pill is rattling Novo Nordisk and Eli Lilly
02:29pm, Thursday, 05'th Feb 2026
Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide,
Structure Therapeutics' GLP-1 drug candidate, aleniglipron, has helped people lose up to 15% of their body weight. Its share price has tripled in the past year, suggesting investors have already price
Edible Garden to Participate in ECRM's Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, February 10–12, 2026
08:09am, Thursday, 05'th Feb 2026
BELVIDERE, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leading provider of controlled environment agricultur
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
02:51pm, Wednesday, 04'th Feb 2026
Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging a
Eli Lilly Is Dominating the GLP-1 Wars as Novo Nordisk Sales Tank
02:39pm, Wednesday, 04'th Feb 2026
The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly ( NYSE:LLY ) and Novo Nordisk ( NYSE:NVO ) has intensified following their latest fourth-quarter earnings reports.
Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do
02:26pm, Wednesday, 04'th Feb 2026
Eli Lilly and Company defies valuation skeptics, posting 45% revenue growth and 96% EPS growth in 2025, with 2026 guidance projecting $80–83 billion in revenue and $33.5–35 EPS. LLY's manufacturin
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
11:20am, Wednesday, 04'th Feb 2026
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of inn
Eli Lilly Proves Its GLP-1 Dominance Again, Raising My Price Target
10:26am, Wednesday, 04'th Feb 2026
Eli Lilly delivered robust Q4 results, with revenue up 43% YoY and EPS beating consensus by $0.61. LLY's 2026 guidance calls for $80–83B revenue and $33.50–35 non-GAAP EPS, outpacing consensus and
Novo Nordisk CEO on 2026 Forecast and GLP-1 Pricing
02:39pm, Tuesday, 03'rd Feb 2026
Novo Nordisk CEO Mike Doustdar discusses the company's updated 2026 sales guidance, forecasting a decline of 5 to 13% at constant exchange rates. Doustdar highlights the strong uptake of Novo Nordisk'
Global Partners Declares Fourth-Quarter 2025 Cash Distribution of $0.7600 on Common Units
08:30am, Friday, 30'th Jan 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
VANCOUVER, BC / ACCESS Newswire / January 29, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce positive interim resu
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolera
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.
08:30pm, Wednesday, 28'th Jan 2026
Eli Lilly's stock trades at more than 30 times forward earnings, which is a steep price to pay right now. Amgen is a much cheaper option by comparison.
This top stock-picker spotted Nvidia and GLP-1s early — and made over 200%. Here's what he's buying now.
07:50am, Wednesday, 28'th Jan 2026
Citrini Research founder James Van Geelen identifies potential big money trends and stakes his claim far ahead of the crowd.
